KYVERNA THERAPEUTICS INC (KYTX) Stock Price, Quote, News and Overview
NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD
KYTX Quote, Performance and Key Statistics
2.78
-0.06 (-2.11%)
The current stock price of KYTX is 2.78 USD. In the past month the price decreased by -17.99%. In the past year, price decreased by -90.03%.
KYTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. The company is headquartered in Emeryville, California and currently employs 119 full-time employees. The company went IPO on 2024-02-08. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
Company Info
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 112
Company Website: https://kyvernatx.com/
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What is the stock price of KYVERNA THERAPEUTICS INC today?
The current stock price of KYTX is 2.78 USD. The price decreased by -2.11% in the last trading session.
What is the ticker symbol for KYVERNA THERAPEUTICS INC stock?
The exchange symbol of KYVERNA THERAPEUTICS INC is KYTX and it is listed on the Nasdaq exchange.
On which exchange is KYTX stock listed?
KYTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KYVERNA THERAPEUTICS INC stock?
12 analysts have analysed KYTX and the average price target is 26.72 USD. This implies a price increase of 861.29% is expected in the next year compared to the current price of 2.78. Check the KYVERNA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KYVERNA THERAPEUTICS INC worth?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 120.01M USD. This makes KYTX a Micro Cap stock.
How many employees does KYVERNA THERAPEUTICS INC have?
KYVERNA THERAPEUTICS INC (KYTX) currently has 112 employees.
What are the support and resistance levels for KYVERNA THERAPEUTICS INC (KYTX) stock?
KYVERNA THERAPEUTICS INC (KYTX) has a resistance level at 2.82. Check the full technical report for a detailed analysis of KYTX support and resistance levels.
Should I buy KYVERNA THERAPEUTICS INC (KYTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KYTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KYTX, evaluating the profitability, health, valuation and growth aspects
- KYVERNA THERAPEUTICS INC (KYTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KYVERNA THERAPEUTICS INC (KYTX) Sales and EPS estimates to see what analysts future expectations are.
- KYVERNA THERAPEUTICS INC (KYTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KYVERNA THERAPEUTICS INC (KYTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- KYVERNA THERAPEUTICS INC (KYTX) Stock Chart to make your own analysis
- KYVERNA THERAPEUTICS INC (KYTX) Latest news and press-releases to stay up to date.
Does KYVERNA THERAPEUTICS INC (KYTX) stock pay dividends?
KYTX does not pay a dividend.
When does KYVERNA THERAPEUTICS INC (KYTX) report earnings?
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of KYVERNA THERAPEUTICS INC (KYTX)?
KYVERNA THERAPEUTICS INC (KYTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.67).
What is the Short Interest ratio of KYVERNA THERAPEUTICS INC (KYTX) stock?
The outstanding short interest for KYVERNA THERAPEUTICS INC (KYTX) is 7.26% of its float. Check the ownership tab for more information on the KYTX short interest.
KYTX Technical Analysis
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYTX. The financial health of KYTX is average, but there are quite some concerns on its profitability.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS decreased by -97.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.91% | ||
| ROE | -34.74% | ||
| Debt/Equity | 0 |
KYTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to KYTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.